About
NeuroQore, Inc., is set to commercialize a new patented monophasic repetitive transcranial magnetic stimulation (rTMS) system with a potentially improved remission rate. The first unit of the NeuroQore rTMS system was installed at the Royal Ottawa Mental Health Centre in July 2015 and successfully passed tolerability testing on healthy volunteers in a pilot project. The company is now in the midst of recruiting patients for the next round of testing. Preliminary clinical data is promising and has prompted installation of more units.
Technologies
Outlook
Mobile Friendly
Keywords
medical device
repetitive transcranial magnetic stimulation
depression treatment
medical and diagnostic laboratories
clinical trials
clinical research collaboration
transcranial magnetic stimulation
services
neuromodulation treatments
medical technology
neuroscience
neurobehavioral conditions
stigma reduction in mental health
neuroscience research
biotech
depression therapy
treatment-resistant depression
neurobehavioral disorder solutions
neurotechnology innovation
b2b
medical devices
electroconvulsive therapy alternatives
brain stimulation technology
mental health
healthcare
brain stimulation
neuromodulation
innovative neurotherapy
acute suicidality treatment
biotechnology
Company Information
-
Employees 3
-
Founded 2012
Location
300 California St, San Francisco, California, United States, 94104
